Valeant Pharmaceuticals International (NYSE:VRX)

CAPS Rating: 2 out of 5

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

Results 1 - 20 of 57 : 1 2 3 Next »

Recs

0
Member Avatar Kenji94 (47.53) Submitted: 1/6/2016 6:51:44 PM : Underperform Start Price: $100.12 VRX Score: +5.40

A gargantuan amount of debt, combined with a decline in revenue won't bode well for VRX.

Recs

0
Member Avatar drmanand (29.27) Submitted: 11/13/2015 11:14:48 PM : Outperform Start Price: $74.49 VRX Score: +28.68

Should be able to come out of the scandal eventually. Might be good entry point.

Recs

2
Member Avatar joaquingrech (96.94) Submitted: 11/11/2015 10:20:06 AM : Outperform Start Price: $82.05 VRX Score: +20.17

unless there is outright fraud, this thing is soooo cheap right now

Recs

0
Member Avatar km00nster (< 20) Submitted: 11/10/2015 11:15:22 AM : Underperform Start Price: $80.04 VRX Score: -22.74

Going to the 60's. CEO selling, everyone selling, I'm shorting. Nasty stuff

Recs

0
Member Avatar roymarshall (29.70) Submitted: 11/5/2015 3:15:30 PM : Underperform Start Price: $77.80 VRX Score: -26.90

R&O massive fraud lawsuits in December. How can anyone invest in this now? If fraud were found. ..shares are worthless.

Recs

0
Member Avatar jpmgator06 (95.32) Submitted: 11/1/2015 3:35:27 PM : Underperform Start Price: $97.16 VRX Score: -3.24

The next Enron

Recs

6
Member Avatar TMFOpie (87.33) Submitted: 10/28/2015 3:05:52 PM : Outperform Start Price: $115.04 VRX Score: -11.28

Not without controversy for sure but considering what's happened over the last couple of months and what they have in assets and potential earnings I think the stock will outperform a rather lukewarm market over the next several years.

Recs

1
Member Avatar TMFInnovator (< 20) Submitted: 10/23/2015 3:45:22 PM : Outperform Start Price: $170.18 VRX Score: -44.42

Highly controversial, and they'll surely make the headlines of many news stories during the next year.

But as long as they can prove they aren't double-booking revenue (i.e. revenue is only recognized once it is actually delivered to the patient), I think the "Enron" allegations go away and the emotions eventually simmer down. And I think there is a place in the healthcare value chain for Valeant -- efficiently allocating capital across smaller pharmaceutical companies.

Reserving the right to be wrong (especially with the short term volatility!), but putting a green thumb on this one.

http://ir.valeant.com/investor-relations/news-releases/news-release-details/2015/Valeant-Pharmaceuticals-Responds-To-Erroneous-Report/default.aspx

Recs

1
Member Avatar o9l9900ol (< 20) Submitted: 10/23/2015 10:38:55 AM : Outperform Start Price: $119.79 VRX Score: -14.61

many of us knew what valeant was doing but did not think it was illegal-further more it was way overdone. l kilo

Recs

1
Member Avatar Hendrickson71 (< 20) Submitted: 10/22/2015 4:18:02 PM : Outperform Start Price: $117.06 VRX Score: -12.90

This is going to be amazing. Consensus price targets are so much higher than current trade. It's ridiculous. This is only going higher.

Recs

0
Member Avatar DLester78 (56.80) Submitted: 10/21/2015 1:44:22 PM : Underperform Start Price: $88.58 VRX Score: -9.54

Also for me to poop on. Anytime a business makes money without earning it, they fail long term. The junk bond party is over and when the books get a solid audit cavity search, you will see how being smart instead of working hard got these a holes and the investors who are still there a nice big enron hangover. Too bad Mr Ackman didn't know this company was a sham.

Recs

2
Member Avatar SmartAce (99.90) Submitted: 10/21/2015 1:35:27 PM : Outperform Start Price: $148.01 VRX Score: -30.51

sigh
s?
verb
1.
emit a long, deep, audible breath expressing sadness, relief, tiredness, or a similar feeling.

Recs

0
Member Avatar DoubleAmerica (97.09) Submitted: 10/21/2015 1:07:08 PM : Underperform Start Price: $92.69 VRX Score: -5.23

Uhoh

Recs

0
Member Avatar solutionorppt (45.37) Submitted: 10/2/2015 12:38:11 PM : Underperform Start Price: $174.20 VRX Score: +45.08

The Valeant model of buy-eviscerate-profit only works so long as there is more to buy to keep distracting from the fact that this isn't really a pharma company.

It's just a M&A machine - all the scientists (even on the business side) have jumped ship over the last few years.

Recs

0
Member Avatar manirg (< 20) Submitted: 8/6/2015 12:02:43 PM : Outperform Start Price: $241.16 VRX Score: -52.14

Undervalued

Recs

1
Member Avatar benyboy (< 20) Submitted: 7/14/2015 6:48:14 PM : Outperform Start Price: $237.20 VRX Score: -50.20

its good...

Recs

1
Member Avatar NechesInvst (99.64) Submitted: 6/19/2015 11:17:33 AM : Outperform Start Price: $230.93 VRX Score: -48.88

Just checking to see if Bill Ackman can pick growth companies.

Recs

0
Member Avatar stocky5 (36.28) Submitted: 6/18/2015 10:00:17 AM : Outperform Start Price: $232.34 VRX Score: -48.88

Forward PEG is 0.67 (CHEAP), with a forward growth rate of over 27%. The stock is near oversold levels, creating a good entry point. Extremely well run company with strong shareholder friendly activist oversight.

Recs

0
Member Avatar luremaster (24.50) Submitted: 5/8/2015 3:57:19 AM : Outperform Start Price: $221.42 VRX Score: -47.45

great management

Recs

0
Member Avatar moneyman999 (53.33) Submitted: 2/15/2015 1:44:00 AM : Underperform Start Price: $168.17 VRX Score: +35.25

Simply overvalued,volitilty will be high but gains will be low.

Results 1 - 20 of 57 : 1 2 3 Next »

Featured Broker Partners